The recent surge in investments into niche pharmaceutical companies, particularly those focusing on groundbreaking therapies and challenging drug development programs, has fueled what some are calling "High Investor Pharma." While the possibility for blockbuster treatments and impressive returns is undeniable, the connected risks are also considera